TABLE 3.
Therapeutics intervening viral replication process
| Target | Specific effect/target molecule | Intervention(s) | Status of SARS‐CoV‐2 trial | Sponsor/collaborators | NCT number |
|---|---|---|---|---|---|
| Protease | 3CLpro |
†1 ASC09/ritonavir †2 lopinavir/ritonavir |
Not applicable | First Affiliated Hospital of Zhejiang University, Ascletis Pharmaceuticals Co., Ltd. | NCT04261907 |
| 3CLpro |
†1 ASC09F + Oseltamivir †2 Ritonavir + Oseltamivir †3 Oseltamivir |
Phase 3 | Tongji Hospital | NCT04261270 | |
| 3CLpro | Darunavir and Cobicistat | Phase 3 | Shanghai Public Health Clinical Center | NCT04252274 | |
| 3CLpro | Ganovo + ritonavir ± interferon nebulization | Phase 4 | The Ninth Hospital of Nanchang, Ascletis Pharmaceuticals Co., Ltd. | NCT04291729 | |
| 3CLpro | Lopinavir/ritonavir | Phase 3 | Darrell Tan, St. Michael's Hospital, Toronto; Jiangxi Qingfeng Pharmaceutical Co. Ltd. | NCT04321174, NCT04295551 | |
| 3CLpro |
†1 Lopinavir/ritonavir †2 Hydroxychloroquine sulfate |
Phase 2 | Asan Medical Center | NCT04307693 | |
| 3CLpro |
†1 Lopinavir/ritonavir †2 Hydroxychloroquine sulfate †3 Baricitinib (Janus kinase inhibitor) †4 Sarilumab (anti‐IL‐6 receptor) |
Phase 2 | Lisa Barrett, Nova Scotia Health Authority, Dalhousie University | NCT04321993 | |
| RdRp | RdRp |
†1 Favipiravir combined with Tocilizumab †2 Favipiravir †3 Tocilizumab |
Not applicable | Peking University First Hospital | NCT04310228 |
| RdRp | Remdesivir | Phase 3 | Gilead Sciences; U.S. Army Medical Research and Development Command; Institut National de la Santé Et de la Recherche Médicale, France; Capital Medical University, Chinese Academy of Medical Sciences; Capital Medical University; Gilead Sciences; National Institute of Allergy and Infectious Diseases (NIAID) | NCT04323761, NCT04302766, NCT04315948, NCT04252664, NCT04257656, NCT04292899, NCT04292730, NCT04280705 | |
| RdRp | Ribavirin | Not applicable | Jiangsu Famous Medical Technology Co., Ltd. | NCT04306497 | |
| RdRp | Galidesivir (BCX4430) | Phase 1 | BioCryst Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID) | NCT03891420 | |
| RdRp | Triazavirin | Phase 3 | Health Commission of Heilongjiang province | ChiCTR2000030001 |
Note: †1, †2, †3, and †4 are different arms of parallel intervention.